Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Qin Jiang; Shuai Pang; Yifang Xia; Hongmei Sun; Yingying Yu

doi:10.1155/2021/2472444

Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Evid Based Complement Alternat Med. 2021 Nov 9:2021:2472444. doi: 10.1155/2021/2472444. eCollection 2021.

Authors

Qin Jiang¹, Shuai Pang², Yifang Xia³, Hongmei Sun⁴, Yingying Yu⁵

Affiliations

¹ Department of Clinical Laboratory, Jiaozhou Central Hospital, Qingdao 266300, China.
² Department of Blood Transfusion, Yantai Yuhungding Hospital, Yantai 264000, China.
³ Department of Imaging, Zhangqiu District People's Hospital, Jinan 250200, China.
⁴ Hospital Infection-Control Department, Zhangqiu District People's Hospital, Jinan 250200, China.
⁵ Department of Pharmacy, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao 266035, China.

Abstract

Objective: To investigate the clinical value of lentinan combined with (125)I brachytherapy in the treatment of recurrent ovarian cancer.

Methods: A total of 160 patients with recurrent ovarian cancer admitted at Jiaozhou Central Hospital from June 2009 to October 2015 were enrolled in this study and randomly divided into observation group (80 cases) and control group (80 cases). The control group received chemotherapy. Observation group (80 cases) was treated with lentinan combined with (125)I brachytherapy on the basis of control group, and the efficacy, adverse reactions, and Karnofsky Performance Scale (KPS) and quality of life scale (QOL) scores of the two groups were analyzed and compared.

Results: After treatment, the levels of CA125, CA199, and CA724 in the 2 groups were markedly lower than those before treatment, and the observation group was lower than the control group (P < 0.05). After treatment, the proportion of CD4⁺/CD8⁺ cells and helper T cells and NK cells in the control group remarkably depleted, while the proportion of CD4⁺/CD8⁺ cells, NK cells, and B cells in the observation group increased significantly compared to that before treatment, and the level of IgA, IgG, and IgM in the control group decreased, while that in the observation group showed no conspicuous difference compared with that before chemotherapy (P > 0.05). The effective rate of observation group (85%) was higher than that of control group (75%) (P < 0.05). The overall survival of patients in the control group was (16.2 ± 2.04) months and that of the observation group was (24.8 ± 1.8) months. KPS and QOL scores in both groups were enormously higher than those before treatment, and the observation group was higher than the control group (P < 0.05). The incidence of hemoglobin reduction, leukopenia, aglobulia, granulocytopenia, nausea and vomiting, hepatorenal toxicity, and neurovirulence in the observation group was significantly lower than that in the control group.

Conclusion: Lentinan combined with (125)I brachytherapy is effective in treating recurrent ovarian cancer, with mild adverse reactions and good tolerance.